{"id":13649,"date":"2023-01-16T10:48:52","date_gmt":"2023-01-16T09:48:52","guid":{"rendered":"https:\/\/udic.es\/?p=13649"},"modified":"2024-02-16T10:14:01","modified_gmt":"2024-02-16T09:14:01","slug":"new-drug-for-early-stage-alzheimers-disease","status":"publish","type":"post","link":"https:\/\/udic.es\/en\/new-drug-for-early-stage-alzheimers-disease\/","title":{"rendered":"new drug for early-stage Alzheimer&#8217;s disease"},"content":{"rendered":"<p>On Epiphany, the U.S. Food and Drug Administration approved a new drug for early-stage Alzheimer&#8217;s disease or for patients with mild cognitive impairment. This drug, lecanemab, moderately slows the rate of cognitive decline in a way that is noticeable to patients.<\/p>\n<p>The Hospital Universitari General de Catalunya, through the Clinical Research Unit (UDIC) led by Dr. Ernest Balaguer, has participated in the phase 2 and phase 3 trial of this drug. In both we have patients who have been receiving the medication openly for years.<\/p>\n<p>Lecanemab is marketed under the name Leqembi and has been developed by the companies Esai and Biogen. In the third phase of clinical trials, it was observed that the drug achieved a 27% slowdown in cognitive decline after 18 months.<\/p>\n<p class=\"p1\"><span class=\"s1\">Leqembi eliminates insoluble aggregates of beta-amyloid protein, patients who received this treatment recorded a significant reduction in beta-amyloid plaque, as demonstrated by amyloid PET. The accumulation of amyloid beta in the brain is a precursor of Alzheimer&#8217;s disease.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>On Epiphany, the U.S. Food and Drug Administration approved a new drug for early-stage Alzheimer&#8217;s disease or for patients with mild cognitive impairment. This drug, lecanemab, moderately slows the rate of cognitive decline in a way that is noticeable to patients. The Hospital Universitari General de Catalunya, through the Clinical Research Unit (UDIC) led by&#8230;<\/p>\n","protected":false},"author":2,"featured_media":9345,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[132,129,135,1],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>new drug for early-stage Alzheimer&#039;s disease - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica<\/title>\n<meta name=\"description\" content=\"On Epiphany, the U.S. Food and Drug Administration approved a new drug for early-stage Alzheimer&#039;s disease or for patients with mild cognitive impairment.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/udic.es\/en\/new-drug-for-early-stage-alzheimers-disease\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"new drug for early-stage Alzheimer&#039;s disease - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\" \/>\n<meta property=\"og:description\" content=\"On Epiphany, the U.S. Food and Drug Administration approved a new drug for early-stage Alzheimer&#039;s disease or for patients with mild cognitive impairment.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/udic.es\/en\/new-drug-for-early-stage-alzheimers-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci%c3%b3-Cl%c3%adnica-447149502490430\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-16T09:48:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-02-16T09:14:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Area-privada5.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"5056\" \/>\n\t<meta property=\"og:image:height\" content=\"1752\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Tito Surribas\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tito Surribas\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/udic.es\/en\/new-drug-for-early-stage-alzheimers-disease\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/udic.es\/en\/new-drug-for-early-stage-alzheimers-disease\/\"},\"author\":{\"name\":\"Tito Surribas\",\"@id\":\"https:\/\/udic.es\/#\/schema\/person\/a8ae8ae960ad58f89663d1d0a2199d1e\"},\"headline\":\"new drug for early-stage Alzheimer&#8217;s disease\",\"datePublished\":\"2023-01-16T09:48:52+00:00\",\"dateModified\":\"2024-02-16T09:14:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/udic.es\/en\/new-drug-for-early-stage-alzheimers-disease\/\"},\"wordCount\":166,\"publisher\":{\"@id\":\"https:\/\/udic.es\/#organization\"},\"image\":{\"@id\":\"https:\/\/udic.es\/en\/new-drug-for-early-stage-alzheimers-disease\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Area-privada5.jpg\",\"articleSection\":[\"Alzeimer\",\"Alzeimer\",\"News\",\"Uncategorised\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/udic.es\/en\/new-drug-for-early-stage-alzheimers-disease\/\",\"url\":\"https:\/\/udic.es\/en\/new-drug-for-early-stage-alzheimers-disease\/\",\"name\":\"new drug for early-stage Alzheimer's disease - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\",\"isPartOf\":{\"@id\":\"https:\/\/udic.es\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/udic.es\/en\/new-drug-for-early-stage-alzheimers-disease\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/udic.es\/en\/new-drug-for-early-stage-alzheimers-disease\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Area-privada5.jpg\",\"datePublished\":\"2023-01-16T09:48:52+00:00\",\"dateModified\":\"2024-02-16T09:14:01+00:00\",\"description\":\"On Epiphany, the U.S. Food and Drug Administration approved a new drug for early-stage Alzheimer's disease or for patients with mild cognitive impairment.\",\"breadcrumb\":{\"@id\":\"https:\/\/udic.es\/en\/new-drug-for-early-stage-alzheimers-disease\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/udic.es\/en\/new-drug-for-early-stage-alzheimers-disease\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/udic.es\/en\/new-drug-for-early-stage-alzheimers-disease\/#primaryimage\",\"url\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Area-privada5.jpg\",\"contentUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Area-privada5.jpg\",\"width\":5056,\"height\":1752,\"caption\":\"Area privada5\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/udic.es\/en\/new-drug-for-early-stage-alzheimers-disease\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/udic.es\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"new drug for early-stage Alzheimer&#8217;s disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/udic.es\/#website\",\"url\":\"https:\/\/udic.es\/\",\"name\":\"UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\",\"description\":\"Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\",\"publisher\":{\"@id\":\"https:\/\/udic.es\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/udic.es\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/udic.es\/#organization\",\"name\":\"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica\",\"url\":\"https:\/\/udic.es\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/udic.es\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png\",\"contentUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png\",\"width\":408,\"height\":123,\"caption\":\"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica\"},\"image\":{\"@id\":\"https:\/\/udic.es\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci\u00f3-Cl\u00ednica-447149502490430\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/udic.es\/#\/schema\/person\/a8ae8ae960ad58f89663d1d0a2199d1e\",\"name\":\"Tito Surribas\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/udic.es\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ae5f603516ade2643999845ead05442c?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ae5f603516ade2643999845ead05442c?s=96&d=mm&r=g\",\"caption\":\"Tito Surribas\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"new drug for early-stage Alzheimer's disease - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","description":"On Epiphany, the U.S. Food and Drug Administration approved a new drug for early-stage Alzheimer's disease or for patients with mild cognitive impairment.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/udic.es\/en\/new-drug-for-early-stage-alzheimers-disease\/","og_locale":"en_US","og_type":"article","og_title":"new drug for early-stage Alzheimer's disease - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","og_description":"On Epiphany, the U.S. Food and Drug Administration approved a new drug for early-stage Alzheimer's disease or for patients with mild cognitive impairment.","og_url":"https:\/\/udic.es\/en\/new-drug-for-early-stage-alzheimers-disease\/","og_site_name":"UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","article_publisher":"https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci%c3%b3-Cl%c3%adnica-447149502490430\/","article_published_time":"2023-01-16T09:48:52+00:00","article_modified_time":"2024-02-16T09:14:01+00:00","og_image":[{"width":5056,"height":1752,"url":"https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Area-privada5.jpg","type":"image\/jpeg"}],"author":"Tito Surribas","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Tito Surribas","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/udic.es\/en\/new-drug-for-early-stage-alzheimers-disease\/#article","isPartOf":{"@id":"https:\/\/udic.es\/en\/new-drug-for-early-stage-alzheimers-disease\/"},"author":{"name":"Tito Surribas","@id":"https:\/\/udic.es\/#\/schema\/person\/a8ae8ae960ad58f89663d1d0a2199d1e"},"headline":"new drug for early-stage Alzheimer&#8217;s disease","datePublished":"2023-01-16T09:48:52+00:00","dateModified":"2024-02-16T09:14:01+00:00","mainEntityOfPage":{"@id":"https:\/\/udic.es\/en\/new-drug-for-early-stage-alzheimers-disease\/"},"wordCount":166,"publisher":{"@id":"https:\/\/udic.es\/#organization"},"image":{"@id":"https:\/\/udic.es\/en\/new-drug-for-early-stage-alzheimers-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Area-privada5.jpg","articleSection":["Alzeimer","Alzeimer","News","Uncategorised"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/udic.es\/en\/new-drug-for-early-stage-alzheimers-disease\/","url":"https:\/\/udic.es\/en\/new-drug-for-early-stage-alzheimers-disease\/","name":"new drug for early-stage Alzheimer's disease - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","isPartOf":{"@id":"https:\/\/udic.es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/udic.es\/en\/new-drug-for-early-stage-alzheimers-disease\/#primaryimage"},"image":{"@id":"https:\/\/udic.es\/en\/new-drug-for-early-stage-alzheimers-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Area-privada5.jpg","datePublished":"2023-01-16T09:48:52+00:00","dateModified":"2024-02-16T09:14:01+00:00","description":"On Epiphany, the U.S. Food and Drug Administration approved a new drug for early-stage Alzheimer's disease or for patients with mild cognitive impairment.","breadcrumb":{"@id":"https:\/\/udic.es\/en\/new-drug-for-early-stage-alzheimers-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/udic.es\/en\/new-drug-for-early-stage-alzheimers-disease\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/udic.es\/en\/new-drug-for-early-stage-alzheimers-disease\/#primaryimage","url":"https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Area-privada5.jpg","contentUrl":"https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Area-privada5.jpg","width":5056,"height":1752,"caption":"Area privada5"},{"@type":"BreadcrumbList","@id":"https:\/\/udic.es\/en\/new-drug-for-early-stage-alzheimers-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/udic.es\/en\/"},{"@type":"ListItem","position":2,"name":"new drug for early-stage Alzheimer&#8217;s disease"}]},{"@type":"WebSite","@id":"https:\/\/udic.es\/#website","url":"https:\/\/udic.es\/","name":"UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","description":"Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","publisher":{"@id":"https:\/\/udic.es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/udic.es\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/udic.es\/#organization","name":"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica","url":"https:\/\/udic.es\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/udic.es\/#\/schema\/logo\/image\/","url":"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png","contentUrl":"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png","width":408,"height":123,"caption":"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica"},"image":{"@id":"https:\/\/udic.es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci\u00f3-Cl\u00ednica-447149502490430\/"]},{"@type":"Person","@id":"https:\/\/udic.es\/#\/schema\/person\/a8ae8ae960ad58f89663d1d0a2199d1e","name":"Tito Surribas","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/udic.es\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ae5f603516ade2643999845ead05442c?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ae5f603516ade2643999845ead05442c?s=96&d=mm&r=g","caption":"Tito Surribas"}}]}},"_links":{"self":[{"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/posts\/13649"}],"collection":[{"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/comments?post=13649"}],"version-history":[{"count":2,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/posts\/13649\/revisions"}],"predecessor-version":[{"id":13653,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/posts\/13649\/revisions\/13653"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/media\/9345"}],"wp:attachment":[{"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/media?parent=13649"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/categories?post=13649"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/tags?post=13649"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}